Attached files
file | filename |
---|---|
EX-31.2 - SOX SECTION 302 CFO CERTIFICATION - Purthanol Resources Ltd | exhibit31-2.htm |
EX-32.1 - SOX SECTION 906 CEO AND CFO CERTIFICATION - Purthanol Resources Ltd | exhibit32-1.htm |
EX-31.1 - SOX SECTION 302 CEO CERTIFICATION - Purthanol Resources Ltd | exhibit31-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended May 31, 2010
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________ to _______________
Commission File Number 000-33271
GLOBAL BIOTECH CORP
(Exact name of registrant as specified in its charter)
DELEWARE | 98-0229951 |
(State of Incorporation) | (I.R.S. Employer Identification No.) |
2711 Centreville Rd suite 400 | 19808 |
(Address of principal executive offices) | (Zip Code) |
(613) 269-3030
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [ X ] No [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large Accelerated filer [ ] | Accelerated Filer [ ] | Non-Accelerated Filer [ ] |
Smaller Reporting Company [ X ] |
Indicate by check mark whether the registrant is a shell company (as determined in Rule 12b-2 of the Exchange Act).
Yes [ X ]
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.
Yes [ ] No [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS:
As of July 12,2010, the aggregate market value of the issuer's common stock based on its reported price on the OTC Bulletin Board held by non-affiliates of the issuer was approximately $3,380,600.
As of July 12, 2010, the Registrant had 67,661,990 shares of Common Stock outstanding.
INDEX
PART I: FINANCIAL INFORMATION
Item 1. Financial Statements
Balance Sheets at May 31, 2010 (Unaudited), November 30, 2009
Statements of Operations (Unaudited) for the Three months and Six months ended May 31, 2010 and May 31, 2009 and from Inception (November 2, 1998) to May 31, 2010.
Statement of Cash Flows (Unaudited) for the Six months ended May 31, 2010 and May 31, 2009 and from Inception (November 2, 1998) to May 31, 2010.
Notes to the Financial Statements (Unaudited).
Item 2. Plan of Operations
Item 4T. Controls and Procedures
PART II: OTHER INFORMATION
Item 6. Exhibits and Reports On Form
SIGNATURES
Amended 10QA
In order to correct several items in Section 4T- Controls and Procedures and in Exhibits 31.1, 31.2, we are issuing an amended 10QA for the Quarter Ended May 31, 2010.
Only the amended sections have been included in this filing. All other sections remain as they were filed with the original filing of our 10Q for May 31, 2010, dated July 12, 2010. This 10QA filing should be read in conjunction with our original 10Q filing of May 31, 2010, dated July 12, 2010.
Item 4T. CONTROLS AND PROCEDURES
QUARTERLY EVALUATION OF THE COMPANYS DISCLOSURE CONTROLS AND INTERNAL CONTROLS.
As of July12, 2010, the date of the report, our Principal Executive Officer (President) and Chief Financial Officer evaluated the effectiveness of the design and operation of the Companys disclosure controls and procedures as defined in Rule 13a -15(e) under the Securities Exchange act of 1934, as amended. Based upon that evaluation, the Principal Executive and Financial Officers concluded that, as of July 12, 2010, the Companys disclosure controls and procedures are effective.
Further, there was no change during the last quarter in the Companys internal control over financial reporting that has materially affected or is likely to materially affect, the Companys internal control over financial reporting.
Part II Item6
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
GLOBAL BIOTECH CORP. (Registrant) |
|
Dated December 21, 2010 | By: /s/ Louis Greco |
President |